acastipharma.com - Wutah bathi EPS kuartalan ACST

Acasti Pharma (ACST) relies on innovative drug delivery methods to combat rare pathologies. Patent protection of formulas curbs competition, although a capital deficit weakens the firm's position. Geopolitical tensions and disruptions in reagent supplies are hindering global tests. The quarterly percentage change in EPS reflects net profit dynamics, where the current value is 56.20, revealing the margin's resilience to costs.

ACST: Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan Acasti Pharma Inc. 04.07.2022 - 28.10.2024

Acasti Pharma (ACST) - rincian metrik lan laporan keuangan

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham acastipharma.com|ACST - Rega prakiraan analis

- rincian nilai pasar emiten:

Kapitalisasi pasar Acasti|ACST - Rega Tumbas Perusahaan

- indikator nilai aset resik miturut neraca:

Nilai Akuntansi saben Saham Acasti Pharma|ACST - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku acastipharma.com|ACST - Nilai Total Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

Total Utang marang Modal Acasti Pharma|ACST - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal acastipharma.com|ACST - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Acasti|ACST - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Acasti Pharma|Rasio cepet acastipharma.com

- informasi bathi lan kelipatan valuasi:

ACST - Bathi resik|Proyeksi bathi mangsa ngarep Acasti Pharma|ACST - Pangali P/E|Pangali Forward P/E acastipharma.com|ACST - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Acasti|ACST - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Acasti Pharma|ACST - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan acastipharma.com|ACST - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Acasti Pharma

- indikator pendapatan dodolan lan penghasilan bisnis:

ACST - Total pendapatan perusahaan|Prakiraan volume dodolan acastipharma.com|ACST - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Acasti

Analisis wiwitan perusahaan:Acasti Pharma

Quarterly EPS growth measures the dynamics of net income per share compared to the same period last year, reflecting the efficiency of value generation for shareholders. Analyzing the current quarterly EPS rate allows for an assessment of how licensing revenues and Acasti Pharma (ACST) developments in treating cardiac pathologies can ensure the business's financial stability amidst market volatility.

Karo sapa Acasti Pharma saingan